Mesenchymal Stem Cells Overexpressing Interleukin-10 Promote Neuroprotection in Experimental Acute Ischemic Stroke
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Interleukin (IL)-10 is a contributing factor to neuroprotection of mesenchymal stem cell (MSC) transplantation after ischemic stroke. Our aim was to increase therapeutic effects by combining MSCs and ex vivo IL-10 gene transfer with an adeno-associated virus (AAV) vector using a rat transient middle cerebral artery occlusion (MCAO) model. Sprague-Dawley rats underwent 90 min MCAO followed by intravenous administration of MSCs alone or IL-10 gene-transferred MSCs (MSC/IL-10) at 0 or 3 hr after ischemia reperfusion. Infarct lesions, neurological deficits, and immunological analyses were performed within 7 days after MCAO. 0-hr transplantation of MSCs alone and MSC/IL-10 significantly reduced infarct volumes and improved motor function. Conversely, 3-hr transplantation of MSC/IL-10, but not MSCs alone, significantly reduced infarct volumes (p < 0.01) and improved motor function (p < 0.01) compared with vehicle groups at 72 hr and 7 days after MCAO. Immunological analysis showed that MSC/IL-10 transplantation significantly inhibits microglial activation and pro-inflammatory cytokine expression compared with MSCs alone. Moreover, overexpressing IL-10 suppressed neuronal degeneration and improved survival of engrafted MSCs in the ischemic hemisphere. These results suggest that overexpressing IL-10 enhances the neuroprotective effects of MSC transplantation by anti-inflammatory modulation and thereby supports neuronal survival during the acute ischemic phase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammatory mechanisms in ischemic stroke: role of inflammatory cells
Jin, R., Yang, G., & Li, G. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1109766 · Cited by 1,521
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926
Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke
Vu, Q., Xie, K., Eckert, M., Zhao, W., & Cramer, S. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000278 · Cited by 235
Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models
Rapti, K., Louis-Jeune, V., Kohlbrenner, E., Ishikawa, K., Ladage, D., Zolotukhin, S., Hajjar, R. J., & Weber, T. (2012) · Molecular Therapy · doi:10.1038/mt.2011.177 · Cited by 170 · cited 1×
“Although administration of an AAV vector encoding rat IL-10 is reportedly neuroprotective against cerebral ischemia, neutralizing AAV antibodies are found in 20%–40% of adult humans and some animal species.(22,43) In the presence of neutralizing AAV antibodies, more than double the amount of the AAV vector is needed.”
BackgroundHoward, D. B., Powers, K., Wang, Y., & Harvey, B. K. (2008) · Virology · doi:10.1016/j.virol.2007.10.007 · Cited by 149 · cited 1×
“Despite its most frequent use for gene therapy, the AAV vector has the potential risk of cytotoxicity and viral DNA integration into the host genome.(41,42) Although administration of an AAV vector encoding rat IL-10 is reportedly neuroprotective against cerebral ischemia, neutralizing AAV antibodies are found in 20%–…”
BackgroundNovel therapeutic strategies targeting innate immune responses and early inflammation after stroke
Shichita, T., Ago, T., Kamouchi, M., Kitazono, T., Yoshimura, A., & Ooboshi, H. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07941.x · Cited by 136 · cited 1×
“IL-10, a key anti-inflammatory cytokine in MSC neuroprotection, suppresses expression of various pro-inflammatory cytokines, such as IFN-g, IL-1b, IL-2, IL-6, and TNF-a, in the inflammatory environment.(16,17,27) In addition, in vitro cell culture studies have shown that IL-10 reduces apoptosis of primary cortical neu…”
Background
Cited by
Shattering barriers toward clinically meaningful MSC therapies
Levy, O., Kuai, R., Siren, E. M. J., Bhere, D., Milton, Y., Nissar, N., De Biasio, M., Heinelt, M., Reeve, B., Abdi, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba6884 · Cited by 694
Post-stroke inflammation—target or tool for therapy?
Lambertsen, K. L., Finsen, B., & Clausen, B. H. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1930-z · Cited by 465
Interleukins and Ischemic Stroke
Zhu, H., Hu, S., Li, Y., Sun, Y., Xiong, X., Hu, X., Chen, J., & Qiu, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828447 · Cited by 363
Dabrowska, S., Andrzejewska, A., Lukomska, B., & Janowski, M. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1571-8 · Cited by 298
The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke
Cunningham, C. J., Redondo-Castro, E., & Allan, S. M. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18776802 · Cited by 242
“Transplantation of MSCs overexpressing IL-10 led to decreased microglial activation and pro-inflammatory cytokine (IL-6, TNFa and IL-1b) concentrations in the brain after stroke compared with non-modified MSCs and vehicle.(125) Administration of IL-10-MSCs was also neuroprotective leading to decreased neuronal degener…”
Background
Metadata
- Authors
- Nakajima, M., Nito, C., Sowa, K., Suda, S., Nishiyama, Y., Nakamura-Takahashi, A., Nitahara-Kasahara, Y., Imagawa, K., Hirato, T., Ueda, M., Kimura, K., & Okada, T.
- Venue
- Molecular Therapy - Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 6
- Pages
- 102-111
- ISSN
- 2329-0501 (ISSN-L)
- OpenAlex
- W2704163919
- Cited by
- 135
- References
- 6
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal Stem Cells Overexpressing Interleukin-10 Promote Neuroprotection in Experimental Acute Ischemic Stroke. https://app.cochat.ai/papers/10.1016/j.omtm.2017.06.005
- The paper
- Nakajima, M., Nito, C., Sowa, K., Suda, S., Nishiyama, Y., Nakamura-Takahashi, A., Nitahara-Kasahara, Y., Imagawa, K., Hirato, T., Ueda, M., Kimura, K., & Okada, T. (2017). Mesenchymal Stem Cells Overexpressing Interleukin-10 Promote Neuroprotection in Experimental Acute Ischemic Stroke. Molecular Therapy - Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2017.06.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.